Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Shore Capital says NatWest's return targets are unsustainable

(Sharecast News) - NatWest shares were pulling back slightly on Monday after a strong performance on Friday following a set of stronger-than-expected first-half results, but it wasn't enough to change Shore Capital's 'hold' rating on the stock. NatWest reported that its RoTE in the second quarter was 17.7%, with pre-tax profit of £1.77bn up 4% and around 8% ahead of consensus forecasts, Shore Capital highlighted. Earnings per share were up 12% at 15.3p and 1.5p (11%) ahead of consensus.

The broker raised its fair-value estimate for the stock from 495p to 500p, after the bank upgraded its full-year guidance for both income (from the previous £15.2-15.7bn range to >£16.0bn) and return on tangible equity (from 15-16% to >16%).

However, analyst Gary Greenwood said that the company "may find it difficult to sustain such high returns over the long term".

"While it is good to see guidance upgraded, this should not have come as a huge surprise (indeed we had noted conservatism in the estimates at Q1), noting that consensus was already at £16.0bn and 16.6% for income and RoTE respectively (we were a little lower at £15.7bn and 16.0% respectively)," Greenwood said.

Shore Capital estimates that near-term RoTE will be higher than guidance at around 17.0%, but noted that returns will be limited by competitive pressures (such as tightening mortgage spreads) and the risk for higher taxes on such high returns - speculation has been building that Labour may reverse the cut in the surcharge on bank profits made by the last government.

The stock was down 1.1% at 513.6p by 1557 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.